ProVerum Medical

ProVerum Medical

Private
Dublin, LeinsterHealthcare & Life Scienceshttps://www.proverummedical.com

Last Round

Series B

Aug 25, 2025

Total Funding Raised

$124.7M

Momentum Score

75 /100

Company Overview

ProVerum is a medical device company specializing in innovative solutions for the treatment of benign prostatic hyperplasia, offering a device that is placed in the urethra to alleviate urinary difficulties caused by prostate enlargement.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

BPH treatmentBenign Prostatic HyperplasiaProVee Systemminimally invasive treatmentprostate stentenlarged prostate treatmentnitinol stentlower urinary tract symptomsLUTSurology deviceMIST for BPHoffice-based proceduremedical device salesatraumatic treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ProVerum Medical Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ProVerum Medical Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BAug 25, 2025
GrantMar 8, 2025
Series AJan 11, 2022
GrantMar 12, 2020
SeedJul 12, 2018

Key People

Founding team and executive leadership

Ríona Ní Ghriallais

Chief Technology Officer

Executive Team

ProVerum Medical Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2026

    Grew 20% QoQ, from 41 to 49 employees.

  • Apr 18, 2026

    Monthly visitors increased 533% MoM to 1.8K.

ProVerum Medical Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ProVerum Medical Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ProVerum Medical's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin, Leinster
Employee Range49
Year Founded2015
Last FundingAug 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.